Reaney, Matthew http://orcid.org/0000-0003-2918-722X
Allen, Veleka
Sehnert, Amy J. http://orcid.org/0000-0003-1912-1710
Fang, Liang
Hagège, Albert A. http://orcid.org/0000-0003-4685-6077
Naidu, Srihari S.
Olivotto, Iacopo http://orcid.org/0000-0003-1751-9266
Funding for this research was provided by:
MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb
Article History
Accepted: 10 April 2022
First Online: 2 June 2022
Declarations
:
: Support of this analysis and manuscript was provided by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb. Medical writing support was provided by IQVIA and PharmaGenesis, Oxford, with funding from MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb.
: Matthew Reaney and Veleka Allen are employees of IQVIA and have received funding from MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for work performed on this study. Amy J. Sehnert is an employee of MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb. Liang Fang is no longer an employee of MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, but is now an employee of Bolt Biotherapeutics Inc. Albert A. Hagège has received financial support from Amicus, Bristol Myers Squibb, Gilead, MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, and Sanofi Genzyme. Srihari S. Naidu has served as a consultant for MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, and Cytokinetics, and has served as an executive committee member for the clinical trial VALOR-HCM (sponsored by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb.). Iacopo Olivotto has received grants and honoraria from MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, Amicus, Shire Takeda, Sanofi Genzyme, and Menarini International and has served as chair of the steering committee for the clinical trial EXPLORER-HCM (sponsored by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb).
: The Bristol Myers Squibb policy on data sharing may be found at ExternalRef removed.
: All aspects of the EXPLORER-HCM (NCT03470545) and MAVERICK-HCM (NCT03442764) studies were conducted in compliance with the Health Insurance Portability Accountability Act of 1996 (USA). Institutional review board and relevant ethics committee approvals were obtained prior to participant enrollment. The study protocols were approved by a US institutional review board: The New England Independent Review Board (197 First Avenue, Suite 250, Needham, MA 02494). Both studies fully adhered to the ethical principles of the Declaration of Helsinki and the specifications of the International Council on Harmonisation and Good Clinical Practice.
: All participants provided informed (written and verbal) consent prior to their participation.
: Not applicable.
: Not applicable.
: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by MR, VA, AJS, and LF. All authors contributed to the drafting and revision of the manuscript and approved the final manuscript.